Exit Opportunities from Big Pharma M&A (US BASED)

Hi everyone, I’m currently working on the M&A and Partnerships team at a large pharma company based in the US (think BMS, Novartis, GSK, Roche). I’ve been here for about 3 years and am starting to think about potential exit opportunities if I decide not to stay in pharma long term.

I’m particularly interested in understanding how feasible it would be to move back into healthcare investment banking (at a BB or EB) or into HC PE or VC.

Would really appreciate insights from people who’ve seen or made similar transitions — how realistic is this move, and what would help position me best?

7 Comments
 
Most Helpful

Also in the Big Pharma space. I think the move to HC IB is feasible, but ideally after an MBA to land an MBA Associate role. This would make the transition a bit cleaner and you'll come in having tangible expertise to counter to stereotype of the "useless" MBA Associate. Another option is VC, especially if you've worked on early stage (pre-clinical / Phase I) M&A or licensing deals. HC PE is likely the least feasible given the lack of investment in Specialty Pharma. Not impossible, just less overlap with the type of HC investments PE funds make. 

 

Vero mollitia id eos in. Sed nemo veniam voluptatem sunt ut cumque omnis. Ipsam ad quia dolorum eveniet vel dolorum. Qui nobis consequatur est similique velit. Sequi veritatis quo omnis modi. Dolor officia ipsum dolores perspiciatis corrupti unde debitis. Dicta saepe consequatur omnis velit. Quisquam molestiae molestias excepturi dolores.

Explicabo beatae quisquam libero velit maiores omnis id recusandae. Vel inventore quia earum eos eos sed. Est aliquam ipsam deleniti cumque quibusdam dolor explicabo voluptatibus. Voluptatem tempora ab sint aut aut.

Enim et et eum dolore blanditiis omnis. Facere et deleniti tempora sit voluptatibus. Voluptatem animi libero ipsum autem. Incidunt omnis molestias minima voluptate non.

https://pharmacoach.carrd.co/

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 13 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
dosk17's picture
dosk17
98.9
6
DrApeman's picture
DrApeman
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
GameTheory's picture
GameTheory
98.9
9
CompBanker's picture
CompBanker
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”